Study summary · research use only
Serum thymosin alpha 1 levels in normal and pathological conditions
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This review discusses thymosin alpha 1 (Ta1), described as a naturally occurring peptide hormone involved in immune regulation, drawing on human clinical studies. It reports that clinical trials have investigated Ta1 in patients with cancer, infectious diseases, and as a vaccine enhancer. The review reports that serum Ta1 levels significantly lower than those of healthy individuals have been associated with hepatitis B, psoriatic arthritis, multiple sclerosis, and sepsis, and that sputum from cystic fibrosis patients contains lower Ta1 levels than healthy controls. It states that low serum Ta1 levels are predictive of and/or associated with different pathological conditions, and that knowing a patient's baseline serum Ta1 level is described as important for establishing treatment protocols and monitoring over time.
Abstract
Thymosin alpha 1 (Ta1) is a natural occurring peptide hormone that is crucial for the maintenance of the organism homeostasis. It has been chemically synthesized and used in diseases where the immune system is hindered or malfunctioning. Many clinical trials investigate the Ta1 effects in patients with cancer, infectious diseases and as a vaccine enhancer. The number of diseases that could benefit from Ta1 treatment is increasing. To date, questions remain about the physiological basal levels of Ta1 and the most effective dose and schedule of treatment. Evidence is growing that diseases characterized by deregulation of immune and/or inflammatory responses are associated with serum levels of Ta1 significantly lower than those of healthy individuals: to date, B hepatitis, psoriatic arthritis, multiple sclerosis and sepsis. The sputum of cystic fibrosis patients contains lower levels of Ta1 than healthy controls. These data are consistent with the role of Ta1 as a regulator of immunity, tolerance and inflammation. Low serum Ta1 levels are predictive and/or associated with different pathological conditions. In case of Ta1 treatment, it is crucial to know the patient's baseline serum Ta1 level to establish effective treatment protocols and monitor their effectiveness over time.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.